


EndeavorRx® Steps to Treatment

EndeavorRx is the first FDA-authorized prescription digital therapeutic (PDTx) of its kind designed to improve attention function in children with ADHD^{1,2}

As a PDTx, EndeavorRx is delivered directly to a caregiver's tablet or smartphone without requiring an in-office HCP visit. Below are the steps on how patients can get started with treatment—beginning with the initial HCP consultation, to pharmacy fulfillment, activating treatment, and HCP follow-up.



Akili Assist® is committed to supporting caregivers and patients along the journey through our Nurse Navigators and other helpful resources to address questions about EndeavorRx treatment.

Indications for Use

EndeavorRx is a digital therapeutic indicated to improve attention function as measured by computer-based testing in children ages 8-12 years old with primarily inattentive or combined-type ADHD, who have a demonstrated attention issue. Patients who engage with EndeavorRx demonstrate improvements in a digitally assessed measure, Test of Variables of Attention (TOVA®), of sustained and selective attention and may not display benefits in typical behavioral symptoms, such as hyperactivity. EndeavorRx should be considered for use as part of a therapeutic program that may include clinician-directed therapy, medication, and/or educational programs, which further address symptoms of the disorder.

Please see Safety and Cautions on the next page.

Safety:

Of 538 participants using EndeavorRx, 50 participants (9.3%) experienced treatment-related adverse events (probable, likely), and three participants experienced treatment-related adverse events with the digital control, in studies where a control was used. EndeavorRx associated adverse events included frustration (6.1%), headache (1.3%), dizziness (0.6%), emotional reaction (0.4%), nausea (0.4%), and aggression (0.2%). There were no serious adverse events. All adverse events were generally transient. Only 3 events led to device discontinuation, and no subject reported lasting or irreversible effects after discontinuation.

Cautions:

Rx only: Federal law restricts this device to sale by or on the order of a physician. EndeavorRx should only be used by the patient for whom the prescription was written. For medical questions, please contact your child's healthcare provider. If you are experiencing a medical emergency, please dial 911. EndeavorRx is not intended to be used as a stand-alone therapeutic and is not a substitution for your child's medication.

If your child experiences frustration, emotional reaction, dizziness, nausea, headache, eye-strain, or joint pain while playing EndeavorRx pause the treatment. If the problem persists contact your child's healthcare provider. If your child experiences a seizure stop the treatment and contact your child's healthcare provider.

EndeavorRx may not be appropriate for patients with photo-sensitive epilepsy, color blindness, or physical limitations that restrict use of a mobile device; parents should consult with their child's healthcare provider.

Please follow all of your mobile device manufacturer's instructions for the safe operation of your mobile device. For example, this may include appropriate volume settings, proper battery charging, not operating the device if damaged, and proper device disposal. Contact your mobile device manufacturer for any questions or concerns that pertain to your device.

Contact your Akili National Account Manager if you have any questions about the prescribing and pharmacy fulfillment process for EndeavorRx®.

References: **1.** Kollins SH, DeLoss DJ, Cañadas E, et al. A novel digital intervention for actively reducing severity of paediatric ADHD (STARS-ADHD): a randomised controlled trial. *Lancet Digit Health*. 2020;2(4):e168-e178. **2.** De Novo Classification Request for EndeavorRx. US Food and Drug Administration. https://www.accessdata.fda.gov/cdrh_docs/reviews/DEN200026.pdf. Accessed November 24, 2021.



Copyright © 2021 Akili Interactive Labs, Inc. All rights reserved. US-00213. 12/21

Akili, EndeavorRx, Endeavor, and Akili Assist, as well as the logos for each, are trademarks or registered trademarks of Akili Interactive Labs, Inc. Other trademarks are trademarks or registered trademarks of their respective owners.

EndeavorRx® Steps to Treatment

EndeavorRx is the first FDA-authorized prescription digital therapeutic (PDTx) of its kind designed to improve attention function in children with ADHD^{1,2}

As a PDTx, EndeavorRx is delivered directly to a caregiver's tablet or smartphone without requiring an in-office HCP visit. Below are the steps on how patients can get started with treatment—beginning with the initial HCP consultation, to pharmacy fulfillment, activating treatment, and HCP follow-up.



CLICK ON EACH FOR
ADDITIONAL INFORMATION

PhilRx sends a text message to the caregiver and conducts a benefits investigation



Caregiver and child consultation with an HCP to discuss EndeavorRx as a treatment option



- HCP consultations can be conducted virtually or in person
- HCPs are advised to use our Indications for Use and characteristics of our trial participants as a benchmark to assess the appropriate pediatric patients who may benefit from treatment with EndeavorRx®



HCP follows up with caregiver to assess the child's progress in improving attention, in combination with other therapies

an activation code over once payment is the responsible party

mitted to supporting caregivers and patients through our Nurse Navigators and other helpful resources to address questions about EndeavorRx treatment.

Indications for Use

EndeavorRx is a digital therapeutic indicated to improve attention function as measured by computer-based testing in children ages 8-12 years old with primarily inattentive or combined-type ADHD, who have a demonstrated attention issue. Patients who engage with EndeavorRx demonstrate improvements in a digitally assessed measure, Test of Variables of Attention (TOVA®), of sustained and selective attention and may not display benefits in typical behavioral symptoms, such as hyperactivity. EndeavorRx should be considered for use as part of a therapeutic program that may include clinician-directed therapy, medication, and/or educational programs, which further address symptoms of the disorder.

Please see Safety and Cautions on the next page.

START

EndeavorRx® Steps to Treatment

EndeavorRx is the first FDA-authorized prescription digital therapeutic (PDTx) of its kind designed to improve attention function in children with ADHD^{1,2}

As a PDTx, EndeavorRx is delivered directly to a caregiver's tablet or smartphone without requiring an in-office HCP visit. Below are the steps on how patients can get started with treatment—beginning with the initial HCP consultation, to pharmacy fulfillment, activating treatment, and HCP follow-up.




CLICK ON EACH FOR
ADDITIONAL INFORMATION

PhilRx sends a text message to the caregiver and conducts a benefits investigation




Caregiver and child consultation with an HCP to discuss EndeavorRx as a treatment option

→
START



- PhilRx is an online prescription management and delivery pharmacy
- Prescriptions can be sent to PhilRx (Columbus, Ohio) through an electronic health record system, or via phone or fax



HCP follows up with caregiver to assess the child's progress in improving attention, in combination with other therapies

PhilRx provides an activation code to the caregiver once payment is received. PhilRx is the responsible party

PhilRx is committed to supporting caregivers and patients through our Nurse Navigators and other helpful resources. Please reach out to address questions about EndeavorRx treatment.

Indications for Use

EndeavorRx is a digital therapeutic indicated to improve attention function as measured by computer-based testing in children ages 8-12 years old with primarily inattentive or combined-type ADHD, who have a demonstrated attention issue. Patients who engage with EndeavorRx demonstrate improvements in a digitally assessed measure, Test of Variables of Attention (TOVA®), of sustained and selective attention and may not display benefits in typical behavioral symptoms, such as hyperactivity. EndeavorRx should be considered for use as part of a therapeutic program that may include clinician-directed therapy, medication, and/or educational programs, which further address symptoms of the disorder.

Please see Safety and Cautions on the next page.

EndeavorRx® Steps to Treatment

EndeavorRx is the first FDA-authorized prescription digital therapeutic (PDTx) of its kind designed to improve attention function in children with ADHD^{1,2}

As a PDTx, EndeavorRx is delivered directly to a caregiver's tablet or smartphone without requiring an in-office HCP visit. Below are the steps on how patients can get started with treatment—beginning with the initial HCP consultation, to pharmacy fulfillment, activating treatment, and HCP follow-up.



CLICK ON EACH FOR
ADDITIONAL INFORMATION

PhilRx sends a text message to the caregiver and conducts a benefits investigation



Caregiver and child consultation with an HCP to discuss EndeavorRx as a treatment option

→
START



- Caregiver receives a text message from PhilRx containing a confirmation link to start the ordering process
- Prescriber submits prior authorization (PA) to CoverMyMeds®
- PhilRx initiates the PA and sends a key



HCP follows up with caregiver to assess the child's progress in improving attention, in combination with other therapies

PhilRx sends an activation code to the caregiver once payment is received from the responsible party

PhilRx is committed to supporting caregivers and patients through our Nurse Navigators and other helpful resources to address questions about EndeavorRx treatment.

Indications for Use

EndeavorRx is a digital therapeutic indicated to improve attention function as measured by computer-based testing in children ages 8-12 years old with primarily inattentive or combined-type ADHD, who have a demonstrated attention issue. Patients who engage with EndeavorRx demonstrate improvements in a digitally assessed measure, Test of Variables of Attention (TOVA®), of sustained and selective attention and may not display benefits in typical behavioral symptoms, such as hyperactivity. EndeavorRx should be considered for use as part of a therapeutic program that may include clinician-directed therapy, medication, and/or educational programs, which further address symptoms of the disorder.

Please see Safety and Cautions on the next page.

EndeavorRx® Steps to Treatment

EndeavorRx is the first FDA-authorized prescription digital therapeutic (PDTx) of its kind designed to improve attention function in children with ADHD^{1,2}

As a PDTx, EndeavorRx is delivered directly to a caregiver's tablet or smartphone without requiring an in-office HCP visit. Below are the steps on how patients can get started with treatment—beginning with the initial HCP consultation, to pharmacy fulfillment, activating treatment, and HCP follow-up.



CLICK ON EACH FOR
ADDITIONAL INFORMATION

PhilRx sends a text message to the caregiver and conducts a benefits investigation



Caregiver and child consultation with an HCP to discuss EndeavorRx as a treatment option

→
START



- **Activation code is sent to the caregiver via text and email**
- **The price of EndeavorRx® is \$450 for a 3-month prescription**

an activation code once payment is made by the responsible party

HCP follows up with caregiver to assess the child's progress in improving attention, in combination with other therapies

PhilRx is committed to supporting caregivers and patients through our Nurse Navigators and other helpful resources to address questions about EndeavorRx treatment.

Indications for Use

EndeavorRx is a digital therapeutic indicated to improve attention function as measured by computer-based testing in children ages 8-12 years old with primarily inattentive or combined-type ADHD, who have a demonstrated attention issue. Patients who engage with EndeavorRx demonstrate improvements in a digitally assessed measure, Test of Variables of Attention (TOVA®), of sustained and selective attention and may not display benefits in typical behavioral symptoms, such as hyperactivity. EndeavorRx should be considered for use as part of a therapeutic program that may include clinician-directed therapy, medication, and/or educational programs, which further address symptoms of the disorder.

Please see Safety and Cautions on the next page.

EndeavorRx® Steps to Treatment

EndeavorRx is the first FDA-authorized prescription digital therapeutic (PDTx) of its kind designed to improve attention function in children with ADHD^{1,2}

As a PDTx, EndeavorRx is delivered directly to a caregiver's tablet or smartphone without requiring an in-office HCP visit. Below are the steps on how patients can get started with treatment—beginning with the initial HCP consultation, to pharmacy fulfillment, activating treatment, and HCP follow-up.



CLICK ON EACH FOR
ADDITIONAL INFORMATION

PhilRx sends a text message to the caregiver and conducts a benefits investigation

Caregiver and child consultation with an HCP to discuss EndeavorRx as a treatment option



- The EndeavorRx® app can be downloaded from the App Store® or on Google Play™
- Once activated, the child will take EndeavorRx treatment for ~25 minutes a day, 5 days a week over at least 4 consecutive weeks, or as prescribed



HCP follows up with caregiver to assess the child's progress in improving attention, in combination with other therapies

an activation code is provided to the responsible party

PhilRx is committed to supporting caregivers and patients through our Nurse Navigators and other helpful resources to address questions about EndeavorRx treatment.

Indications for Use

EndeavorRx is a digital therapeutic indicated to improve attention function as measured by computer-based testing in children ages 8-12 years old with primarily inattentive or combined-type ADHD, who have a demonstrated attention issue. Patients who engage with EndeavorRx demonstrate improvements in a digitally assessed measure, Test of Variables of Attention (TOVA®), of sustained and selective attention and may not display benefits in typical behavioral symptoms, such as hyperactivity. EndeavorRx should be considered for use as part of a therapeutic program that may include clinician-directed therapy, medication, and/or educational programs, which further address symptoms of the disorder.

Please see Safety and Cautions on the next page.

→
START

EndeavorRx® Steps to Treatment

EndeavorRx is the first FDA-authorized prescription digital therapeutic (PDTx) of its kind designed to improve attention function in children with ADHD^{1,2}

As a PDTx, EndeavorRx is delivered directly to a caregiver's tablet or smartphone without requiring an in-office HCP visit. Below are the steps on how patients can get started with treatment—beginning with the initial HCP consultation, to pharmacy fulfillment, activating treatment, and HCP follow-up.



CLICK ON EACH FOR
ADDITIONAL INFORMATION

PhilRx sends a text message to the caregiver and conducts a benefits investigation



Caregiver and child consultation with an HCP to discuss EndeavorRx as a treatment option

→
START



- HCPs are advised to follow up with patients during and after treatment cycles to discuss results and next steps, same as they would after issuing a drug prescription
- Subsequent refills of EndeavorRx® will be billed and dispensed by PhilRx
- Caregivers can track their child's daily game progress and share updates with HCPs to have more productive conversations



HCP follows up with caregiver to assess the child's progress in improving attention, in combination with other therapies

an activation code is provided to the caregiver once payment is received from the responsible party

PhilRx is committed to supporting caregivers and patients through our Nurse Navigators and other helpful resources to address questions about EndeavorRx treatment.

Indications for Use

EndeavorRx is a digital therapeutic indicated to improve attention function as measured by computer-based testing in children ages 8-12 years old with primarily inattentive or combined-type ADHD, who have a demonstrated attention issue. Patients who engage with EndeavorRx demonstrate improvements in a digitally assessed measure, Test of Variables of Attention (TOVA®), of sustained and selective attention and may not display benefits in typical behavioral symptoms, such as hyperactivity. EndeavorRx should be considered for use as part of a therapeutic program that may include clinician-directed therapy, medication, and/or educational programs, which further address symptoms of the disorder.

Please see Safety and Cautions on the next page.